Work

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-128579

Authors: Anneke D. van Dijk, Peter P. Ruvolo, Fieke W Hoff, Yihua Qiu, Alan S Gamis, Richard Aplenc, Anders E. Kolb, Todd A. Alonzo, Robert B. Gerbing, Eveline S. de Bont, Sophia W.M. Bruggeman, Terzah M Horton, Steven M. Kornblau

Institutions: The University of Texas MD Anderson Cancer Center, University Medical Center Groningen, Children's Mercy Hospital, Children's Hospital of Philadelphia, Alfred I. duPont Hospital for Children, University of Southern California, Children's Oncology Group, Baylor College of Medicine

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2989326966

Cites:

Cited by:

Related to: 10